vrx is a "high beta" stock? hahahaaha
how about google, amzn, tesla, pcln, isrg, nflx = "low beta" stocks? dummy dummy
i never short stock
i buy the common stock
at dip and sell the rebound
want so bad to sell at 22 now
but stock may rise further
due to huge huge buying volume
sell limit order at 21.75 canceled
since i really like huge buying volume
and a positive article by Barron's as
"valeant will hit $90/share" for july?
Do ya buy this argument?
=== Rodman & Renshaw’s Raghuram Selvaraju sees enough catalysts in July for Valeant Pharmaceuticals International (VRX) to warrant his $90 price target. He explains:
Multiple regulatory decisions slated for this month. In our view, July is shaping up to be a busy month for Valeant, given the potential for three regulatory decisions in the coming weeks. On July 19, 2016, Valeant is slated to have its Biologics License Application (BLA) for brodalumab, an investigational anti-interleukin-17 (antiIL-17) monoclonal antibody for the treatment of moderate-to-severe plaque psoriasis, reviewed by an FDA advisory committee. We note that the brodalumab BLA currently carries a PDUFA approval decision date of November 16, 2016. If the panel discussion is favorable, we believe brodalumab could be approved in the U.S. by the PDUFA date. However, at this juncture we do not include any contribution from U.S. sales of brodalumab in our revenue model. Also on July 19, Valeant is slated to receive an approval decision from the FDA on oral Relistor® (methylnaltrexone) for opioid-induced constipation (OIC). In our view, a positive decision could significantly expand the target market for Relistor and may enable it to become a blockbuster with over $1B in annual sales. Finally, we note that on July 21, 2016, Valeant and its partner NicOx S.A. (COX.PA, not rated) are slated to receive an approval decision on Vesneo® (latanoprostene bunod) for the treatment of glaucoma. In our view, this is the highest likelihood approval event for Valeant, and we consider Vesneo to have $500M peak sales potential in the U.S. alone. Since Valeant’s Bausch + Lomb (B+L) division is currently in labeling discussions with the FDA, we believe that timely approval of Vesneo® appears likely. Given these near-term catalysts, we reiterate our Buy rating and $90 price target on Valeant shares.
gotta love this powerful bull market especially in the US ...
=== John Schlifske believes the US is a great place to invest
According to John Schlifske, the US (QQQ) (IWM) is a great place to invest. He believes the US (SPY) will outperform the global markets (ACWI) (VTI) in the long term. He thinks that crises don’t affect the long-term business cycle that much and that the demand level in the economy and consumerism will drive economic growth. Plus, he thinks that demographic changes could have an added advantage for the economy. He said, “five years ago the top age group was fifty, now the top five age groups are below thirty.”